Search research articles
Contact Us
Filters
Showing results (31-40 of 86) with videos related to
Page
of 9
Sort By:
European Urology Oncology
|
January 24, 2025
Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for Treating Advanced Urothelial Carcinoma
David J Benjamin, Arash Rezazadeh Kalebasty, Nataliya Mar
European Urology Oncology
|
March 14, 2024
The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
David J Benjamin, Arash Rezazadeh Kalebasty, Vinay Prasad
BJU International
|
March 6, 2023
Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh
Clinical Medicine Insights. Oncology
|
October 3, 2022
Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
David J Benjamin, Nataliya Mar, Arash Rezazadeh Kalebasty
Nature Reviews. Urology
|
May 13, 2024
Overcoming barriers in cancer care for gender minorities
David J Benjamin, Omid Yazdanpanah, Arash Rezazadeh Kalebasty
BJU International
|
May 14, 2024
A review of vitamin use for the prevention or treatment of prostate cancer
David J Benjamin, Omid Yazdanpanah, Arash Rezazadeh Kalebasty
The Lancet. Oncology
|
April 30, 2022
FDA decisions on new oncological drugs
David J Benjamin, Vinay Prasad, Mark P Lythgoe
Cancers
|
May 13, 2023
Prostate Cancer in Sexual Minorities: Epidemiology, Screening and Diagnosis, Treatment, and Quality of Life
Omid Yazdanpanah, David J Benjamin, Arash Rezazadeh Kalebasty
Journal of Cancer Policy
|
April 14, 2024
Implications of FDA's marketing authorization of hereditary cancer testing
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Journal of Cancer Policy
|
June 9, 2024
Social media engagement of supportive care publications in oncology
Sruthi Ranganathan, David J Benjamin, Alyson Haslam, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 86) with videos related to
Sort By:
Page
of 9
European Urology Oncology
|
January 24, 2025
Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for Treating Advanced Urothelial Carcinoma
David J Benjamin, Arash Rezazadeh Kalebasty, Nataliya Mar
European Urology Oncology
|
March 14, 2024
The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
David J Benjamin, Arash Rezazadeh Kalebasty, Vinay Prasad
BJU International
|
March 6, 2023
Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh
Clinical Medicine Insights. Oncology
|
October 3, 2022
Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
David J Benjamin, Nataliya Mar, Arash Rezazadeh Kalebasty
Nature Reviews. Urology
|
May 13, 2024
Overcoming barriers in cancer care for gender minorities
David J Benjamin, Omid Yazdanpanah, Arash Rezazadeh Kalebasty
BJU International
|
May 14, 2024
A review of vitamin use for the prevention or treatment of prostate cancer
David J Benjamin, Omid Yazdanpanah, Arash Rezazadeh Kalebasty
The Lancet. Oncology
|
April 30, 2022
FDA decisions on new oncological drugs
David J Benjamin, Vinay Prasad, Mark P Lythgoe
Cancers
|
May 13, 2023
Prostate Cancer in Sexual Minorities: Epidemiology, Screening and Diagnosis, Treatment, and Quality of Life
Omid Yazdanpanah, David J Benjamin, Arash Rezazadeh Kalebasty
Journal of Cancer Policy
|
April 14, 2024
Implications of FDA's marketing authorization of hereditary cancer testing
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Journal of Cancer Policy
|
June 9, 2024
Social media engagement of supportive care publications in oncology
Sruthi Ranganathan, David J Benjamin, Alyson Haslam, et al.
Page
of 9